ArticleEmerging infectious diseases2024
Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Impact of delayed blood donation sample processing and testing on SARS-CoV-2 serological assay results in an evolving pandemic response.Transfusion · 2026Article
- Hidden asymptomatic breakthrough infection in a proof-of-concept longitudinal study on SARS-CoV-2 vaccine recipients.Journal of biomedical science · 2026Article
- Previous COVID-19 Vaccination Modulates Type I Interferon and Natural Killer Cell Responses During SARS-CoV-2 Infection.Journal of cellular and molecular medicine · 2026Article
- Associations of blood donor and product characteristics with platelet transfusion outcomes.Blood advances · 2026Article
- Workflow‑Based Information Management Framework for Multicenter Research Studies: Design and Development.Online journal of public health informatics · 2026Article
- Review
- The impact of statistical adjustment for assay performance on inferences from SARS-CoV-2 serological surveillance studies.American journal of epidemiology · 2025Article
- From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.Vaccine · 2025Article
- COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.Epidemiologia (Basel, Switzerland) · 2025Article
- Identification of undetected SARS-CoV-2 infections by clustering of Nucleocapsid antibody trajectories.Nature communications · 2025Article
- Detection of SARS-CoV-2 Reinfections Using Nucleocapsid Antibody Boosting.Emerging infectious diseases · 2025Article
- Proportions of US Blood Donors With Serological Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections Who Reported Survey-Based Diagnosed Infections During July 2020-December 2022.Open forum infectious diseases · 2025Article
- Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study.Open forum infectious diseases · 2025Article
- Blood donor SARS-CoV-2 infection or vaccination and adverse outcomes in plasma and platelet transfusion recipients.Transfusion · 2025Article
- Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection".Microbiology spectrum · 2025Article
- Vaccination caused an underestimation of the cumulative incidence of SARS-CoV-2 infection.Microbiology spectrum · 2025Article
- Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China.Frontiers in immunology · 2025Article
- Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants.Access microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleocapsid antibody assays can be used to estimate SARS-CoV-2 infection prevalence in regions implementing spike-based COVID-19 vaccines. However, poor sensitivity of nucleocapsid antibody assays in detecting infection after vaccination has been reported. We derived a lower cutoff for identifying previous infections in a large blood donor cohort (N = 142,599) by using the Ortho VITROS Anti-SARS-CoV-2 Total-N Antibody assay, improving sensitivity while maintaining specificity >98%. We validated sensitivity in samples donated after self-reported swab-confirmed infections diagnoses. Sensitivity for first infections in unvaccinated donors was 98.1% (95% CI 98.0-98.2) and for infection after vaccination was 95.6% (95% CI 95.6-95.7) based on the standard cutoff. Regression analysis showed sensitivity was reduced in the Delta compared with Omicron period, in older donors, in asymptomatic infections, <30 days after infection, and for infection after vaccination. The standard Ortho N antibody threshold demonstrated good sensitivity, which was modestly improved with the revised cutoff.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.